Toxicity that occurs in patients includes hyperglycemia as genes encoding most glycolytic enzymes are under transcriptional control by PI3K/AKT [7].We designed a novel PI-103 prodrug (RIDR-PI-103) such that the PI3K inhibitor PI-103 would only be released under high oxidative stress conditions found in the tumor milieu. The gene discussed is AKT1; the disease is Hyperglycemia.